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Abstract
Background: Although the prevalence of metabolic syndrome has been studied in nationally representative 
populations, little is known about its prevalence specifi cally among working adults. Because corporations are 
often the primary payers of health-care costs in the United States, they have a vested interest in knowing the 
impact of metabolic syndrome in employed individuals.
Methods: A total of 4188 employees (83.4% male, 92.1% Caucasian, average age 40.8 years) of a midwestern U.S. 
manufacturing corporation participated in a health risk appraisal and biometric screening in 2006 and also 
used the company’s medical plan. Those with metabolic syndrome were compared to those without metabolic 
syndrome in terms of their 2006 health risks, health conditions, health-care costs, pharmacy costs, short-term 
disability costs, and a measure of on-the-job productivity loss known as presenteeism.
Results: A total of 30.2% of employees met the criteria for metabolic syndrome and were more likely to also have 
a variety of additional health risks and health conditions compared to those without metabolic syndrome. For ex-
ample, 9.4% of those with metabolic syndrome self-reported having diabetes compared to 1.4% of those without 
metabolic syndrome. Health-care costs, pharmacy costs, and short-term disability costs were signifi cantly higher 
for those with metabolic syndrome compared to those without metabolic syndrome, and increasing numbers of 
metabolic syndrome health risks were associated with greater numbers of employees reporting on-the-job pro-
ductivity losses (presenteeism).
Conclusions: Because metabolic syndrome is prevalent among the employees of this manufacturing company 
and is associated with signifi cant economic costs, employers would be wise to address the health risks of employ-
ees through health promotion programs and benefi t plan designs that help individuals improve their health and 
receive appropriate health screenings and medical care.
Introduction
Several definitions of metabolic syndrome have been published, making it diffi cult to compare prevalence 
rates estimated by different studies. This cluster of meta-
bolic risk factors was fi rst called “syndrome X” in 1988.1 Ten 
years later the World Health Organization (WHO)2 proposed 
its defi nition. The National Cholesterol Education Program 
(NCEP) developed its own defi nition in 2001 known as Adult 
Treatment Panel III (ATP III)3 and in 2005, the International 
Diabetes Federation (IDF) introduced yet another defi nition.4 
Finally, the American Heart Association and National Heart, 
Lung and Blood Institute have recently confi rmed the value 
of the ATP III defi nition with some minor modifi cations, in-
cluding the addition of a medication component. Therefore, 
the current worldwide standard for metabolic syndrome is 
three or more of the following criteria: waist circumference 
(≥102 cm in men, ≥88 cm in women, or body mass index 
(BMI) >30 kg/m2), triglycerides ≥150 mg/dL or taking med-
ication for triglycerides, high-density lipoprotein cholesterol 
(HDL-C) <40 mg/dL for men or <50 mg/dL for women or 
taking medication for HDL, blood pressure ≥130/85 mmHg 
or taking medication for blood pressure, and fasting glucose 
≥100 mg/dL or taking medication for glucose.5
Some research has compared the prevalence of meta-
bolic syndrome with these different criteria. One study 
compared the prevalence of metabolic syndrome using the 
WHO2 and ATP III3 defi nitions among 8608 subjects.6 About 
86% of people were classifi ed the same by both defi nitions.6 
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Employees of a large manufacturing corporation head-
quartered in the midwestern United States were offered 
an annual HRA and wellness screening beginning in 2004. 
Likely due to the use of a $600 benefi ts incentive, the screen-
ing achieved extremely high participation rates (from 85% 
to 95% of employees) since the program began in 2004. The 
HRA and screening was conducted at the work site by staff 
of the company’s medical department and completed on 
company time. Each screening took about 15 minutes to 
complete. Of the 5277 individuals who were employed in 
2006, 5243 (99.4%) participated in the HRA. Of the HRA par-
ticipants, 4188 (79.9%) participated in the company’s medi-
cal plan. This is the population of interest in this study. The 
majority of employees were male (83.4%) and Caucasian 
(92.1%) and an average age of 40.8 years old. About 80% of 
employees were hourly and 20% were salaried.
Health risks
The HRA was based on Healthier People, Version 4.0 (The 
Carter Center of Emory University, Atlanta, GA, 1991), and 
enhanced over time on the basis of the most recent morbidity 
and mortality studies in cooperation with the University 
of Michigan’s Health Management Research Center (Ann 
Arbor, MI). Each participant completing the HRA received 
an individualized report summarizing their health risks 
and suggestions for health improvement. The health risks 
and their cut points can be found in Table 1.
The HRA also included data from a biometric screening 
that used venipuncture for blood glucose and lipid panel 
variables and measured height and weight. A third-party 
laboratory was contracted for the venipuncture procedure. 
The screening results provided the information on meta-
bolic syndrome risk factors. In this study, the risks currently 
accepted as the best indicators of metabolic syndrome were 
used.5 Therefore, in this employed population, the follow-
ing risks were used: blood pressure ≥130/85 mmHg, fasting 
glucose ≥100 mg/dL, triglycerides ≥150 mg/dL, and HDL-C 
<40 mg/dL in men and <50 mg/dL in women. Waist cir-
cumference was not measured at this company’s screening 
until 2007, so a BMI >30 kg/m2 was used as a surrogate. As 
indicated in the current criteria of metabolic syndrome, if 
individuals have a BMI greater than 30 kg/m2, it can safely 
be assumed that their waist circumference exceeds the risk 
level.17 Individuals with at least three of the risks were con-
sidered to have metabolic syndrome.
In addition to asking employees about the presence of 16 
biological and lifestyle health-risk factors, the HRA included 
the following question about the presence of several chronic 
diseases: Do you currently have any of the following? The 
list included: seasonal allergies, asthma, arthritis, back pain, 
cancer (any type), chronic bronchitis/emphysema, depres-
sion, diabetes mellitus, heartburn, heart disease, high cho-
lesterol, hypertension, irritable bowel syndrome, kidney 
disease, migraine, osteoporosis, and stroke. Additionally, 
respondents were asked whether they were either being 
treated by a physician or currently taking medications for 
Although the overall estimates were very similar (23.9% and 
25.1% prevalence rates), signifi cant differences were noted 
among certain population subgroups. For example, among 
African-American men, 16.5% had metabolic syndrome 
using the ATP III criteria whereas 24.9% met the defi nition 
of the WHO. The ATP III defi nition of metabolic syndrome is 
more focused on its relationship to cardiovascular disease, 
which may account for some of the difference with the WHO 
defi nition.2
A German study compared the WHO, ATP III, and IDF 
defi nitions of metabolic syndrome to identify the difference 
in prevalence rates among individuals who already had type 
2 diabetes.7 The degree of agreement was much stronger be-
tween the ATP III and IDF defi nitions (κ = 0.69) compared 
to the WHO versus IDF (κ = 0.12) and WHO versus ATP III 
(κ = 0.17). An epidemiological study in India also compared 
the WHO, ATP III, and IDF defi nitions and found the three 
defi nitions identifi ed different individuals. While 841 of the 
2350 subjects were positively identifi ed as having metabolic 
syndrome by at least one of the defi nitions, only 224 were 
identifi ed by all three defi nitions.8 Other studies using the 
ATP III defi nition of metabolic syndrome among nation-
ally representative datasets have found prevalence rates in 
the United States ranging from 22.7%9 to 23.7%.10 In both 
of those studies, prevalence rates varied widely in ethnic 
subgroups.
Few studies have determined the prevalence of metabolic 
syndrome risks in working populations. One such study in 
a worksite found a prevalence rate of 27%,11 which is in line 
with population-based studies. Another study of a working 
population in 2001 identifi ed groups of risks measured by 
a Health Risk Appraisal (HRA) questionnaire using clus-
ter analysis. One of the four identifi ed clusters was termed 
the “biometric cluster.”12 It was apparent to those research-
ers that a cluster of health risks, including blood pressure, 
cholesterol, and overweight, often traveled together, as did 
other clusters of risks such as a psychological cluster (life 
satisfaction, stress, perceived health) and a risk-taking clus-
ter (alcohol use, safety belt use, smoking).
Many studies have found a strong association between 
metabolic syndrome risks with both heart disease and 
diabetes.13–22 But again, none of these studies was conducted 
specifi cally in a working population. Considering that employ-
ees at this corporation have access to low-cost health care as 
well as a relatively large income compared to many subjects 
in nationally representative samples, it is hypothesized that 
the prevalence of metabolic syndrome will be lower in this 
population. As corporations are the main payers of health-
care costs in the United States, they have a vested interest 
in identifying the magnitude of metabolic syndrome risks in 
employed populations and also in knowing if those risks are 
associated with other health risks or medical conditions or 
economic outcomes such as health-care costs or productiv-
ity. Many companies offer wellness programs to encourage 
employees to maintain their health and reduce health risks, 
such as those that comprise metabolic syndrome.
The aim of this study was to identify the prevalence of 
metabolic syndrome risks in employees of a large manufac-
turing corporation. Furthermore, the association between 
metabolic syndrome and other health risks and conditions 
was also determined in this employed population. The eco-
nomic costs (health-care costs, pharmaceutical costs, short-
term disability absenteeism, and on-the-job productivity 
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STD cost. They were also signifi cantly older (42.9 years vs. 
40.4 years, P < 0.05). At this company, STD pays a weekly 
benefi t for full-time, hourly employees and is paid at 100%. 
The maximum duration of STD benefi ts paid is 26 weeks. If 
the employee is still disabled after 26 weeks, they are eligible 
for another 26 weeks on STD, but will not be paid. Long-term 
disability coverage is not offered to the majority of employ-
ees, so the cost of that benefi t is not included here. As with 
medical and pharmacy claims, the STD data were merged 
with the employee health and personnel information.
Presenteeism
On-the-job productivity was measured by a subset of 
the Work Limitations Questionnaire (WLQ) included in the 
HRA to assess the health-related impact on work productiv-
ity. Eight questions (two from each WLQ work domain) were 
selected from the original 25 WLQ questions and the eight-
item subset of questions have been used in previous stud-
ies.23–26 These questions evaluated the percentage of time at 
work that a physical or emotional problem interfered with 
any of the following work areas: time management (work-
ing the required number of hours, starting work on time); 
physical work (repeating the same hand motions, using 
work equipment); mental/interpersonal activities (concen-
tration, teamwork); and output demand (completing the 
require amount of work, working to your capability). More 
detail on the eight-item WLQ questionnaire can be found 
in a previous study27 and the eight items can be found in 
Table 2. Employees were asked to base their answers on the 
conditions that they had reported. If an individual reported 
either currently having a given condition, or being under 
medical care or taking medication, they were considered to 
have that particular condition. If employees reported taking 
medication for diabetes, high blood pressure, or high cho-
lesterol, those criteria were considered in the metabolic syn-
drome risk determination as well.
Medical and pharmacy claims
Medical and pharmacy claims were also available for the 
population studied and were provided by a third-party ad-
ministrator. The medical insurance provider and pharmacy 
benefi t manager for this company provided each claim in-
curred by each employee in 2006 via encrypted transmis-
sion. Medical claims from 2006 were summed to create a 
total for each individual as were pharmacy claims. These 
claims data were then merged with employee health-risk 
and personnel data.
Short-term disability absences
Short-term disability (STD) absences were used as a 
measure of productivity loss. STD absences in 2006 were 
summed for each individual, as was their STD cost, which 
was provided by the company. A total of 232 individuals 
(5.5% of the study population) incurred a nonpregnancy 
STD cost during the study time period. Those with nonpreg-
nancy STD costs were signifi cantly more likely to be female 
(25.9% vs. 16.2%, P < 0.0001) compared to those without an 
Table 1. Description of Health Risks Measured by a Health Risk Appraisal 
Questionnaire and Screening
Risk High-risk cut
Alcohol >14 Drinks per week
Blood pressurea ≥130/85 mmHg
Body mass indexa >30.0 kg/m2
Cholesterol >239 mg/dL
Disease Seasonal allergies, asthma, arthritis, back pain, 
cancer (any type), chronic bronchitis/emphysema, 
depression, diabetes mellitus, heartburn, heart 
disease, high cholesterol, hypertension, irritable 
bowel syndrome, kidney disease, menopause, 
migraine, osteoporosis, or stroke
Drug use to relax Almost every day or sometimes
High-density lipoprotein 
cholesterola
<40 for men, <50 for women
Illness days >5 Days in the past year
Glucosea ≥100 mg/dL 
Job satisfaction Partly or not satisfi ed
Life satisfaction Partly or not satisfi ed
Perceived health Fair or poor
Physical activity <1 Time per week
Safety belt use <100%
Smoking Current cigarette smoker
Stress Score >18 (based on a composite score from answers 
to marital status, personal loss, life satisfaction, 
perception of health, hours of sleep, and social ties)
Triglyceridesa ≥150 mg/dL
aMetabolic syndrome risk factors.
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(n = 2922, 69.8%) had less than three of the risk factors while 
1266 individuals (30.2%) were considered to have metabolic 
syndrome because they had three or more of the risks.
The demographics of individuals with and without met-
abolic syndrome were then analyzed, and the results are 
shown in Table 4. Those with metabolic syndrome (n = 1266) 
were nearly 4 years older than those without the syndrome 
(43.1 vs. 39.6 years, P < 0.0001). A signifi cantly greater per-
centage of those with metabolic syndrome were male com-
pared to those without metabolic syndrome (89.6% vs. 80.7%, 
P < 0.0001). Because of these signifi cant differences, and also 
because other researchers have identifi ed that age and gen-
der are signifi cant confounding variables,8,9 all further anal-
yses controlled for age and gender. A greater percentage of 
those with metabolic syndrome had education less than a 
previous 2 weeks of work and to rate any impairment on a 
5-point scale with options of “none of the time (0%),” “some 
of the time,” “half of the time (50%),” “most of the time,” and 
“all of the time (100%).” Additionally, employees were able to 
select a response of “does not apply to my job,” which was 
treated as a missing answer for that item. The response for 
each domain was judged to be valid if at least one of the two 
items was nonmissing. A dichotomous score (yes/no) indi-
cated whether or not any work limitations were noted for 
any domain (ie, amount of limitation >0%).
Statistical analyses
Differences in continuous and categorical variables in 
individuals with and without metabolic syndrome were 
tested using t-tests and chi-squared analyses, respectively. 
Logistic and generalized linear models were used to iden-
tify factors associated with the presence of metabolic syn-
drome while controlling for demographic variables. The 
Cochran–Armitage test for trend was used to analyze 
whether or not the percentage of employees reporting any 
presenteeism was higher as the number of metabolic syn-
drome risks increased. All analyses were conducted using 
SAS 9.1 software. (SAS Institute Inc., Cary, NC). This study 
was approved by the University of Michigan’s Institutional 
Review Board.
Results
First the prevalence of the fi ve metabolic syndrome 
health risks in this employed population was explored. 
Table 3 shows the percentage of employees with each of the 
fi ve metabolic syndrome risk factors as well as by number of 
metabolic syndrome risks.
In this group of people employed in a manufacturing 
company, 36.6% had high blood pressure or reported the use 
of blood pressure medication, 32.0% had a BMI >30, 32.0% 
had a fasting glucose level greater than or equal to 100 or 
reported using diabetes medication, 33.1% had low HDL-C 
or reported taking cholesterol medication, and 42.2% met 
the criteria for high triglycerides. In all, only 23.1% (n = 968) 
of the population had none of the fi ve risks, while 3.4% 
(n = 144) had all fi ve risks. Almost 70% of the population 
Table 2. Description of Eight-Item Work Limitations Questionnaire
In the past 2 weeks, how much of the time did your physical health or emotional problems make it 
diffi cult for you to do the following?
Item Subscale
1. Work the required number of hours Time management
2. Start on your job as soon as you arrived at work
3. Repeat the same hand motions over and over again while working Physical work
4. Use your equipment (eg, phone, pen, keyboard, computer mouse)
5. Concentrate on your work Mental/interpersonal
6. Help other people to get work done
7. Do the required amount of work on your job Output
8. Feel you have done what you are capable of doing
Possible answers: None of the time (0%), some of the time, half of the time (50%), most of 
the time, all of the time (100%), does not apply to my job.
Table 3. Prevalence of Metabolic Syndrome Risks in 
Employed Population in 2006
 




Blood pressure ≥130/85 mmHg
(or blood pressure meds)
1534 36.6%
Body mass index >30 kg/m2 1339 32.0%
Fasting glucose ≥100 (or diabetes 
meds)
1341 32.0%
High-density lipoprotein <40 (male), 
<50 (female) (or cholesterol meds)
1385 33.1%
Triglycerides ≥150 1769 42.2%
None of the risks 968 23.1%
Any one of the risks 1042 24.9%
Any two of the risks 912 21.8%
Any three of the risks 706 16.9%
Any four of the risks 416 9.9%
All fi ve of the risks 144 3.4%
<3 of the risks 2922 69.8%
3+ of the risks (metabolic syndrome) 1266 30.2%
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risks are selected from 10 variables that demonstrate strong 
associations with future medical claims costs as determined 
by multiple research studies. These variables include smok-
ing status, physical activity, alcohol consumption, safety 
belt usage, blood pressure, total cholesterol, HDL-C, body 
weight, illness days, and self-assessment of health. The mor-
tality risks are calculated as a function of the rates between 
achievable and appraised probabilities of the deaths from 
all causes in the next 10 years according to a HRA partici-
pant’s age, gender, and health risks. The preventive services 
selected are based on the fi ndings and recommendations of 
the U.S. Preventive Services Task Force Guidelines28 accord-
ing to participants’ age and gender.
Additional self-reported medical conditions were then 
compared for those with and without metabolic syndrome 
and results are found in Table 5. Those with metabolic syn-
drome were signifi cantly more likely to report having arthri-
tis, chronic bronchitis/emphysema, chronic pain, depression, 
diabetes, heart problems, heartburn/acid refl ux, and stroke 
compared to employees without metabolic syndrome, after 
college degree (79.2% vs. 73.3%, P = 0.0462 after controlling 
for age and gender). Hourly employee status, marital status, 
and ethnicity were not signifi cantly different after control-
ling for age and gender.
The additional health risks measured by the HRA were 
also compared for those with and without metabolic syn-
drome. Those with metabolic syndrome were signifi cantly 
more likely also to be at risk for high total cholesterol, ill-
ness days, the use of relaxation medication, perceived phys-
ical health, physical inactivity, safety belt use, and high 
stress after controlling for age and gender. When the over-
all wellness score calculated for each HRA participant was 
compared, employees with metabolic syndrome had a sig-
nifi cantly lower wellness score compared to those without 
metabolic syndrome (73.8 compared to 84.1, P < 0.0001). The 
wellness score is on a scale of 0 to 100 and includes compo-
nents of behavioral health risks, mortality risks, and preven-
tive services usage. Behavioral health risks are weighted the 
most among the three components in the wellness score and 
preventive services weighted the least. The behavioral health 






P valuea(n = 2922) (n = 1266)
Average age 39.6 years 43.1 years <0.0001
% Male 80.7% 89.6% <0.0001
Education level
 Some college or less 73.3% 79.2%   0.0462
 College graduate or more 26.7% 20.8%
Household income
 <$75,000 74.0% 73.8%   0.2458
 ≥$75,000 26.0% 26.2%
Hourly employee status 78.2% 84.0%   0.1264
Married 70.2% 75.8%   0.8748
Caucasian 92.1% 92.0%   0.4257
Health risks
 Alcohol drinks >14 per week 5.6% 4.3%   0.0353
 Cholesterol >240 mg/dL 12.5% 17.2%   0.0011
 >5 Illness days in past year 4.4% 7.0% <0.0001
 Job dissatisfaction 11.6% 12.9%   0.4183
 Life dissatisfaction 14.8% 16.4%   0.2012
 Use relaxation medication 11.6% 17.7% <0.0001
 Poor or fair physical health 8.7% 18.1% <0.0001
 Physical inactivity 12.6% 16.4%   0.0007
 Safety belt use 31.2% 32.9%   0.0377
 Smoking 19.8% 18.5%   0.9000
 High stress 21.2% 26.6% <0.0001
Metabolic syndrome risks
 Blood pressure ≥130/85 (or meds) 21.4% 71.9% <0.0001
 Body mass index >30 14.9% 71.4% <0.0001
 Fasting glucose ≥100 (or meds) 17.2% 66.3% <0.0001
 High-density lipoprotein <40 
(male), <50 (female) (or meds)
19.8% 63.7% <0.0001
 Triglycerides ≥150 24.9% 82.3% <0.0001
Wellness score 84.1 73.8 <0.0001
at-test for age, chi-squared for gender, generalized linear model testing difference in 
demographics and health risks controlling for age and gender.
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controlling for age and gender. After counting up all health 
conditions, the average number of conditions reported by 
participants was signifi cantly greater (P < 0.0001) for those 
with metabolic syndrome (1.01 conditions per person) com-
pared to those without metabolic syndrome (0.68 conditions 
per person).
Workplace outcomes were then considered. The health-
care and pharmaceutical costs of those with and without 
each of the metabolic syndrome risks were compared, as 
were the costs of STD absences and the percent of employees 
reporting any presenteeism. Table 6 contains those results.
When examining the health-care costs, those at risk for 
triglycerides and blood pressure had signifi cantly higher 
health-care costs compared to those not at risk for those 
factors after controlling for age and gender. For four of the 
risk factors (HDL was the exception), those with the risk 
had signifi cantly higher pharmacy costs compared to those 
not at risk for each factor. STD costs were signifi cantly 
higher among those with four of the fi ve risks (again, HDL 
was the exception). The annual STD cost is relatively low 
compared to health-care and pharmacy costs because only 
a small percentage of employees incur an STD claim in any 
1 year, and the cost of that claim is spread over all employ-
ees in each category. The percentage of employees report-
ing any presenteeism was signifi cantly higher for those 
at risk for triglycerides compared to those not at risk for 
triglycerides.
Table 7 shows those cost outcomes by number of meta-
bolic syndrome risks and also compares those with and 
without metabolic syndrome. Those who met the criteria 
for metabolic syndrome (3+ risk factors) had signifi cantly 
higher health-care ($3340 vs. $1788), pharmacy ($570 vs. 
$270), and STD ($106 vs. $59) costs compared to those who 







(95% CI)(n = 2922) (n = 1266)
Allergies 18.0% 19.0% 1.14 (0.96–1.34)
Arthritis 7.4% 14.3% 1.68 (1.35–2.09)
Asthma 2.5% 3.2% 1.41 (0.94–2.11)
Back pain 11.9% 13.0% 1.12 (0.92–1.38)
Cancer 0.6% 0.6% 0.90 (0.38–2.14)
Chronic bronchitis/
emphysema
0.2% 0.9% 3.44 (1.29–9.15)
Chronic pain 3.7% 6.2% 1.55 (1.14–2.10)
Depression 3.9% 6.2% 1.75 (1.29–2.38)
Diabetes 1.4% 9.4% 5.64 (3.92–8.13)
Heart problems 2.2% 5.5% 1.89 (1.31–2.67)
Heartburn or acid refl ux 9.1% 14.9% 1.66 (1.35–2.03)
Migraine headaches 3.5% 2.9% 1.06 (0.71–1.57)
Stroke 0.1% 0.5% 6.85 (1.32–35.53)
Other condition 3.9% 4.1% 0.99 (0.70–1.40)
Average number of 
conditionsb
0.68 1.01 P < 0.0001
aMultivariate logistic regression model adjusting for age and gender.
bMultivariate linear regression model adjusting for age and gender.
Table 6. Workplace Outcomes Associated With 
Metabolic Syndrome Risk Factors
 Not at risk At risk
Annual health care costs
 Blood pressure ≥130/85 or meds $1637 $3330a
 BMI >30 $2114 $2561
 Fasting glucose ≥100 or meds $1837 $3148
 HDL <40 (male), <50 (female) $2289 $2192
 Triglycerides ≥150 $1755 $2944a
Annual pharmacy costs
 Blood pressure ≥130/85 or meds $258 $538a
 BMI >30 $316 $455a
 Fasting glucose ≥100 or meds $258 $578a
 HDL <40 (male), <50 (female) $362 $358
 Triglycerides ≥150 $253 $507a
Annual STD costs
 Blood pressure ≥130/85 or meds $59 $97a
 BMI >30 $60 $101a
 Fasting glucose ≥100 or meds $57 $108a
 HDL <40 (male), <50 (female) $74 $71
 Triglycerides ≥150 $60 $91a
% Reporting any presenteeism
 Blood pressure ≥130/85 or meds 33.7% 35.5%
 BMI >30 33.6% 36.1%
 Fasting glucose ≥100 or meds 33.5% 36.2%
 HDL <40 (male), <50 (female) 34.6% 33.9%
 Triglycerides ≥150 33.1% 36.1%a
aGeneralized linear model P value comparing those with and 
without the risk, 0.05 controlling for age and gender.
Abbreviations: HDL, high-density lipoprotein; BMI, body 
mass index; STD, short-term disability.
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(P < 0.05) for increasing numbers of employees reporting 
presenteeism as the number of risk factors increases. Because 
researchers are not yet confi dent of the appropriate way to 
convert presenteeism losses to dollars, 29–31 that conversion 
was not made here either.
Discussion
In this manufacturing company population, the prevalence 
of metabolic syndrome was 30.2%, which is higher than rates 
reported in nationally representative samples6 as well as work 
site studies in fi nancial,32 aerospace/defense,10 and chemical33 
sectors, which report metabolic syndrome prevalence of 22.6% 
to 27%. Differences seen here may be related to geography. 
This company is headquartered in the midwestern United 
States, which is known to have higher rates of obesity and dia-
betes than some other regions of the country.34Also, most pre-
vious studies of metabolic syndrome used either the WHO or 
ATP III criteria. The latest defi nition of metabolic syndrome, 
did not meet the criteria for metabolic syndrome. Also, 
36.9% of employees with metabolic syndrome reported any 
presenteeism compared to 33.4% of those without metabolic 
syndrome (P < 0.05 after controlling for age and gender). 
When all monetary costs were added together to create a 
total cost for each individual (not shown in Table 7), those at 
risk for metabolic syndrome had costs of $4016 compared to 
$2117 for those not at risk for metabolic syndrome, a differ-
ence of $1899 (P < 0.0001 adjusting for age and gender).
Figure 1 shows the costs of individuals with zero, one, 
two, three, four, and fi ve of the metabolic syndrome risk fac-
tors. As can be seen in the fi gure, health-care, pharmacy, and 
total costs are signifi cantly greater for those with three, four, 
or fi ve risks compared to those with none of the risks. STD 
costs are signifi cantly higher for those with four or fi ve risks 
compared to those with none of the risks.
Figure 2 presents the percentage of employees reporting 
any presenteeism by the number of metabolic syndrome risk 
factors. The Cochran–Armitage test for trend is signifi cant 








% Reporting any 
presenteeism
None of the risks 968 $1544 $202 $56 31.8%
Any one risk 1042 $1530 $245 $55 34.9%
Any two risks 912 $2341 $369a $66 33.2%
Any three risks 706 $3169a $480a $70 35.7%
Any four risks 416 $3683a $618a $148a 39.2%a
All fi ve risks 144 $3190a $875a $160a 37.0%a
No metabolic syndrome 
(<3 risk factors)
2922 $1788 $270 $59 33.4%
Metabolic syndrome 
(3+ risk factors)
1266 $3340b $570b $106b 36.9%b
aGeneralized linear model P value <0.05 compared to those with zero risks, controlling for age 
and gender.
bGeneralized linear model P value <0.05 compared to those without metabolic syndrome, controlling 
for age and gender.



































No Metabolic Syndrome Metabolic Syndrome
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$3,169*
FIG. 1. Annual costs by number of metabolic 
syndrome factors. *Signifi cantly different from 0 
risk category, P < 0.01. Generalized Linear Model 
adjusting for age and gender. Abbreviation: STD, 
short-term disability. 
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bronchitis/emphysema, chronic pain, depression, diabetes, 
heart problems, heartburn, and stroke. While the literature 
provides many examples of the link between heart disease 
and diabetes with metabolic syndrome,12–21 a few studies 
have also shown a relationship between chronic pain and 
metabolic syndrome. Loevinger, et al. found that women 
with the chronic pain condition fi bromyalgia were 5.6 times 
more likely to have metabolic syndrome than healthy con-
trols.38 Another study indicated that individuals with carpal 
tunnel syndrome were three times more likely to also have 
metabolic syndrome.39 The relationship between metabolic 
syndrome and carpal tunnel syndrome is not surpris-
ing given that increased BMI is a key risk factor in both 
conditions.40,41
Although the HRA does not specify type of arthritis 
(rheumatoid or osteoarthritis), some researchers have found 
that metabolic syndrome and rheumatoid arthritis share 
some of the same characteristics such as insulin resistance 
and dyslipidemia.42,43 The relationship between mental 
health and metabolic syndrome is not well understood and 
requires more research.44,45
The results shown in Fig. 1 indicate that workplace cost 
outcomes are signifi cantly higher for those with metabolic 
syndrome compared to those without metabolic syndrome. 
Figure 2 also shows that increasing numbers of metabolic 
syndrome health risks are associated with greater num-
bers of employees reporting on-the-job productivity losses 
(presenteeism).
However, as was shown in Table 5, those with metabolic 
syndrome are also more likely to have other health condi-
tions compared to those without metabolic syndrome. This 
is undoubtedly a factor in the higher costs associated with 
metabolic syndrome. However, since more than half (54.4%) 
of employed individuals with metabolic syndrome do not 
yet have a medical condition, they also require interventions 
to help improve their health risks so they do not reach the 
level of disease.
Limitations
This study was conducted in an employee population 
of a single large manufacturing corporation headquar-
tered in the midwestern United States, which may limit the 
which is used here, identifi es more individuals with meta-
bolic syndrome because of the additional medication compo-
nent. That is, those with normal glucose, blood pressure, or 
HDL but who are taking medication for those conditions to 
keep their values normal will now be counted as high risk for 
metabolic syndrome. It is surprising that in this population, 
which enjoys a relatively high income and excellent access to 
low-cost health care, the prevalence of metabolic syndrome is 
not substantially lower than that found in nationally repre-
sentative studies, which include lower-income adults as well 
as those without health insurance. It appears that the healthy 
worker effect35 (HWE) has no impact on the prevalence of 
metabolic syndrome risks in this population.
A prevalence comparison study in Germany found that 
while the ATP III criteria identifi ed about 20% of the popula-
tion as having metabolic syndrome, the defi nition proposed 
by Grundy et al.5 and used in the current study identifi ed 
around 29% of the population as having metabolic syn-
drome.36 Furthermore, one study of a National Health and 
Nutrition Examination Survey (NHANES) stratifi ed sam-
ple found a metabolic syndrome prevalence of 34.5% using 
the ATP III criteria and 39.0% using the IDF criteria, which 
requires the presence of central obesity.37
Employees in this study population with metabolic syn-
drome are signifi cantly more likely to be male and older com-
pared to those without metabolic syndrome. Furthermore, 
those with metabolic syndrome were more likely to also be 
at risk for the health risks of high total cholesterol, illness 
absence days, the use of relaxation medication, perceived 
physical health, physical inactivity, and high stress. Clearly, 
individuals with metabolic syndrome also have other health 
risks they are dealing with. Indeed, the wellness score, which 
is an overall measure of health risks, is signifi cantly lower for 
individuals with metabolic syndrome (73.8) compared to those 
without metabolic syndrome (84.1, P < 0.0001). Organizations 
that identify individuals with metabolic syndrome would be 
wise to offer a wide variety of health promotion activities to 
help improve the diverse health risks of those employees.
Individuals with metabolic syndrome not only have 
additional health risks, they also have additional health 
conditions. Out of 14 possible health conditions measured 
on the HRA, those with metabolic syndrome were sig-
nifi cantly more likely to report having arthritis, chronic 
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No Metabolic Syndrome Metabolic Syndrome
FIG. 2. Percent reporting any presenteeism by 
number of metabolic syndrome risks. Cochran–
Armitage test for trend, P < 0.05.
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 3.  National Institutes of Health. Third report of the National 
Cholesterol Education Program Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults 
(Adult Treatment Panel III). Executive Summary. Bethesda, 
MDP: National Institutes of Health, National Heart, Lung and 
Blood Institute; 2001 (NIH publ. no. 01-3670)
 4.  Aberti KG, Zimmet P, Shaw J. Metabolic synbdrome—a 
new world-wide defi nition. A consensus statement from the 
International Diabetes Federation. Diabet Med 2006;23:469–480.
 5.  Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, 
Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, 
Spertus JA, Costa F. Diagnosis and management of the meta-
bolic syndrome: An American Heart Association/National 
Heart, Lung, and Blood Institute Scientifi c Statement. Circulation 
2005;112:2735–2752.
 6.  Ford ES, Giles WH. A comparison of the prevalence of the meta-
bolic syndrome using two proposed defi nitions. Diabetes Care 
2003;26:575–581.
 7.  Koehler C, Ott P, Benke I, Hanefeld M. Comparison of the preva-
lence of the metabolic syndrome by WHO, AHA/NHLBI, and IDF 
defi nitions in a German population with type 2 diabetes: The Dia-
betes in German (DIG) study. Horm Metab Res 2007;39:632–635.
 8.  Deepa M, Farooq S, Datta M, Deepa R, Mohan V. Prevalence of 
metabolic syndrome using WHO, ATPIII and IDF defi nitions in 
Asian Indians: the Chennai Urban Rural Epidemiology Study 
(CURES-34). Diabetes Metab Res Rev 2007;23:127–134.
 9.  Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: 
Prevalence and associated risk factor fi ndings in the US popula-
tion from the Third National Health and Nutrition Examination 
Survey, 1988–1994. JAMA 2002;163:427–436.
10.  Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syn-
drome among US adults. JAMA 2002;287:356–359.
11.  Godefroi R, Klementowicz P, Pepler C, Lewis B, McDonough K, 
Goldberg RJ. Metabolic syndrome in a screened worksite sam-
ple: prevalence and predictors. Cardiology 2005;103:131–136.
12.  Braunstein A, Li Y, Hirschland D, McDonald T, Edington DW. 
Internal associations among health-risk factors and risk preva-
lence. Am J Health Behav 2001;25:407–417.
13.Alexander CM, Landsman PB, Teutch SM, et al. NCEP-defi ned 
metabolic syndrome, diabetes, and prevalence of coronary heart 
disease among NHANES III participants age 50 years and older. 
Diabetes 2003;52:1210–1214.
14.  Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic 
syndrome on mortality from coronary heart disease, cardiovas-
cular disease, and all causes in United States Adults. Circulation 
2004;110:1245–1250.
15.  Hu G, Qiao Q, Tuomilehto J, et al. Prevalence of the metabolic 
syndrome and its relation to all-cause and cardiovascular mor-
tality in nondiabetic European men and women. Arch Intern 
Med 2004;164:1066–1076.
16.  Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syn-
drome and total and cardiovascular disease mortality in mid-
dle-aged men. JAMA 2002;288:2709–2716.
17.  Wilson PW, Kannel WB, Silbershatz H et al. Clustering of 
metabolic factors and coronary heart disease. Arch Intern Med 
1999;259:1104–1109.
18.  Grundy S, Hansen B, Smith S, et al. Clinical management of met-
abolic syndrome: Report of the American Heart Association/
National Heart, Lung, and Blood Institute/American Diabetes 
Association conference on scientifi c issues related to manage-
ment. Circulation 2004;109:551–556.
19.  Ninomiya JK, L’Italien G, Criqui MH, et al. Association of the 
metabolic syndrome with history of myocardial infarction and 
stroke in the Third National Health and Nutrition Examination 
Survey. Circulation 2004;109:42–46.
20.  Costa LA, Canani LH, Lisboa HR et al. Aggregation of features 
of the metabolic syndrome is associated with increased preva-
lence of chronic complications in Type 2 diabetes. Diabet Med 
2004;21:252–255.
generalizability of the results. Similar studies should be con-
ducted in a variety of industries to see if the fi ndings are repli-
cated in different demographic and geographic groups. As in 
most worksite studies, HRA participation is voluntary so the 
population studied may not always be representative of the 
entire employee population. However, in this study, a nearly 
universal participation rate (99%) eliminates that problem. The 
cross-sectional nature of this study also does not allow for any 
inference of cause–effect about the associations found.
Another potential limitation of this study is the lack of 
data available on waist circumference. Although the cur-
rently used defi nitions of metabolic syndrome all rely on 
waist circumference, this measurement has been found to 
be subject to large amounts of error, particularly in men. 
One study of metabolic syndrome used both BMI and waist 
circumference and found the two measures to be highly 
correlated.46 Another study compared waist circumfer-
ence, BMI, and waist-to-hip ratio in their ability to predict 
abdominal adipose tissue (which is the true aim of the met-
abolic syndrome obesity risk factor) in men as determined 
by magnetic resonance imaging.47 Results showed that 
waist circumference most uniformly predicts the distribu-
tion of adipose tissue in the abdominal region but that the 
relative strengths of waist circumference and BMI in pre-
dicting abdominal adiposity did not differ signifi cantly. The 
company studied here has added waist circumference to its 
biometric screening in 2007, so a future study will compare 
those results with BMI.
Conclusions
Metabolic syndrome is prevalent in working populations 
in the manufacturing industry. In the case of this predomi-
nantly male population of manufacturing employees, 30.2% 
met the criteria for metabolic syndrome. These employees 
with metabolic syndrome are signifi cantly more likely to 
have a variety of other health risks and health conditions 
compared to those without metabolic syndrome. They also 
have signifi cantly higher health-care, pharmacy, and STD 
absence costs and are more likely to report presenteeism. 
Employers would be wise to address the health risks of 
employees through health promotion programs and benefi t 
plan designs that help individuals improve their health and 
receive appropriate health screenings and medical care.
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